pembrolizumab + carboplatin + etoposide

**Pembrolizumab + carboplatin + etoposide** is a combination therapy used primarily in oncology, notably as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) and in high-grade neuroendocrine tumors. **Pembrolizumab** is a humanized monoclonal antibody that targets and inhibits the programmed death-1 (PD-1) receptor, preventing its engagement with the ligands PD-L1 and PD-L2 on tumor and immune cells, thereby restoring T-cell anti-tumor immunity. **Carboplatin** is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis. **Etoposide** inhibits topoisomerase II, leading to DNA strand breaks and cell death. The combination is designed to maximize anti-tumor efficacy by integrating immunotherapy with cytotoxic chemotherapy. Indications include extensive-stage small cell lung cancer and metastatic high-grade neuroendocrine tumors[4][5][6][1].

Brand names

Keytruda + carboplatin + etoposide

Other names

pembrolizumab plus carboplatin and etoposide